However, they can differ depending on formulations, dose, and timing
For the anti-obesity medications (AOMs): The number of patients being prescribed an AOM continues to increase
Those who were prescribed this drug and were overweight or had obesity were more than seven times more likely to get the diagnosis
Visceral fat, which wraps around organs and increases metabolic risk, dropped more in the treatment group compared to placebo
Clinically Proven Results: Backed by 10 clinical trials, it demonstrates improved moisture, a more even complexion, reduced pores, and enhanced skin tone and texture within just two weeks.
Wegovy contains semaglutide and is approved specifically for weight management in the Australia (16), while Mounjaro acts on two hormone pathways (GLP-1 and GIP) and has demonstrated greater average weight loss in head-to-head clinical trials (17)